200 1st Street SW
844 articles with Mayo Clinic
New Research from nference and Mayo Clinic Suggests Monoclonal Antibody Treatments Prevent Hospitalization for COVID-19 Patients
nference, the AI-driven health technology company, announced publication of two studies providing important evidence that treatment of high-risk, mild to moderate COVID-19 patients with monoclonal antibodies significantly reduces risk of hospitalization.
Mayo Clinic and Debbie's Dream Foundation Hosts a Successful Gasgtroesophageal Cancer Educational Symposium
Mayo Clinic and Debbie's Dream Foundation: Curing Stomach Cancer (DDF) co-hosted the Gastroesophageal Cancer Educational Symposium Clinic on Saturday, July 31, 2021 , in Rochester, Minnesota .
Researchers say transplanting fecal microbiota from the mother into the newborn can reverse the risk for Type 1 diabetes for babies who had been exposed to antibiotic treatments early.
nference and Mayo Clinic Study Confirms Link Between Anemia and Rehospitalization After COVID-19 Infection Clearance
nference today announced publication of a study in iScience that analyzed Mayo Clinic data with nference artificial intelligence (AI) software to suggest that anemia-related laboratory tests should be considered in risk stratification algorithms for COVID-19 patients.
Tetherex Pharmaceuticals Signs Exclusive Worldwide License with Mayo Clinic for Development and Commercialization of a Novel Single-Cycle Adenovirus Vaccine Platform
Tetherex Pharmaceuticals, Inc. today announced that it has executed an exclusive worldwide license with Mayo Clinic for the development and commercialization of a novel single-cycle adenovirus vaccine platform.
Orphazyme said that its OLE trial, which has been running for the past 24 months, showed that arimoclomol could be an effective and safe option in treating Niemann-Pick disease type C.
Spruce Biosciences shared results from two Phase II studies assessing tildacerfont, a non-steroidal, oral antagonist for the treatment of adult patients with classic CAH.
In an eight page letter to U.S. DOH and Human Services Secretary Xavier Becerra, Public Citizen said Woodcock and other FDA officials should resign.
Grail presents its first data from the interventional PATHFINDER trial of Galleri, its multi-cancer early detection blood test. Galleri is now available in the U.S. by prescription.
Mayo Clinic, Kaiser Permanente announce strategic investment in Medically Home to expand access to serious or complex care at home
The provider-led partnership with Medically Home will transform the delivery of acute-level care for patients with serious or complex illnesses.
There was a lot of news and research studies today related to the COVID-19 vaccines. Here’s a look.
The Leukemia & Lymphoma Society Launches IMPACT Research Grants to Help Underserved Patients Access Clinical Trials
Collaborations with Mayo Clinic, Vanderbilt University Medical Center and Weill Cornell Medicine will Increase Representation of Geographically, Ethnically and Economically Underserved Communities in Clinical Trials
Phenomix Sciences Signs Exclusive Technology Licensing Deal With Mayo Clinic for Obesity Phenotype Blood Test
Biomedical startup company Phenomix Sciences (Phenomix) has signed an exclusive technology licensing agreement with Mayo Clinic for a novel blood test that accurately predicts obesity phenotypes. The multi-level “omics” MyPhenome™ test leverages technology developed at Mayo Clinic to analyze genomics, metabolomics and hormone levels.
A coalition of 60 top hospitals and health care institutions have joined forces in a nationwide campaign to encourage adults to get vaccinated against COVID-19.
Tabula Rasa HealthCare and OneOme Combine Powerful Precision Medication Tools to Improve Medication Safety, Efficacy and Adherence
Tabula Rasa HealthCare, Inc®, a leading healthcare technology company advancing the safe use of medications, announced it has partnered with OneOme, co-founded by Mayo Clinic, a provider of solutions for implementing pharmacogenomics in patient care to advance more optimal patient outcomes.
Mayo Clinic announced Wednesday that it has launched two new tech venture companies designed to harness artificial intelligence (AI) and medical algorithms and create “software as medical devices” that clinicians can use to improve treatment across different diseases.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Stella Diagnostics, Inc. announced that they have entered into a Collaborative Research Agreement with the Mayo Clinic to assess the predictability and clinical utility of the Company's STLA101 panel in patients diagnosed with Barrett's esophagus.
Sorrento Announces Subsidiary Company - ADNAB, Inc. - to Develop and Commercialize ADNAB™ Platform Products for Hematological Malignancies and Solid Tumors Based on an Exclusive Technology License From the Mayo Clinic
The ADNAB™ platform was developed and exclusively licensed to Sorrento by the Mayo Clinic Clinical studies utilizing the ADNAB™ platform are ongoing at the Mayo Clinic; and are evaluating multiple platform-generated products in advanced-stage: endometrial cancer, ovarian cancer, angiosarcoma, and B-Cell lymphomas Study LS1681 is a Mayo Investigator-Initiated-Trial (IIT) for relapsed or refractory B-cell lymphomas; and is evaluating rituximab-ADNAB™
Three Lakes Foundation collaborates with Mayo Clinic to advance diagnosis and treatment for devastating lung disease
Three Lakes Foundation announces it is collaborating with Mayo Clinic to increase awareness of pulmonary fibrosis symptoms; improve an understanding of the current diagnostic journey; and develop a remote diagnostic tool that connects patients with appropriate healthcare resources at an earlier and more treatable phase of their illness.